By InvitationNot Applicable

Serial PET MPI in Patients Undergoing Cancer Treatment

United States60 participantsStarted 2023-06-01

Plain-language summary

This study aims to evaluate the effects of cardiotoxic cancer therapies on myocardial blood flow (MBF) and perfusion in a prospective sample of VA patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Veterans Affairs oncology patients who will be initiating chemotherapy * Ability to give consent Exclusion Criteria: * Prior chemotherapy * Prior coronary revascularization (percutaneous coronary intervention, coronary artery bypass grafting) * Anyone with previous invasive or CT (computed tomography) angiogram demonstrating any lesion ≥ 50% stenosis * Known cardiomyopathy defined as rest ejection fraction \< 50% * History of heart and/or another organ transplant * Pregnancy or breast-feeding status

What they're measuring

1

PET myocardial perfusion imaging (MPI).

Timeframe: Baseline (within 1 month prior to the initiation of cancer treatment), during cancer treatment (estimated at 1-6 months), and within 1 month post-cancer treatment completion (approximately 2-9 months)

2

PET myocardial blood flow (MBF) measurement.

Timeframe: Baseline (within 1 month prior to the initiation of cancer treatment), during cancer treatment (estimated at 1-6 months), and within 1 month post-cancer treatment completion (approximately 2-9 months)

Trial details

NCT IDNCT05913999

SponsorUniversity of California, Los Angeles

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-07-31